Vertex Pharmaceuticals (VRTX)

Business Overview

Vertex shows that extreme concentration and strong profits can sit together. Its cystic fibrosis (CF) products, TRIKAFTA/KAFTRIO and ALYFTREK, brought in $11,151M of $12,001M FY2025 revenue, or 92.9%. GAAP net income was $3,953M, and liquid securities were $12.3B at 31 December 2025.

That cash figure predates Vertex's largest acquisition. On 1 September 2026 Vertex completed its all-cash purchase of Crinetics Pharmaceuticals for about $10.0B of equity value, or about $8.8B net of the cash it acquired. The deal added PALSONIFY (paltusotine), an oral treatment for the hormone disorder acromegaly, launched in the US and approved in the EU, plus the development programme atumelnant, giving Vertex a rare endocrine disease business. Vertex expects the deal to start adding to its non-GAAP operating income in 2029. Every FY2025 figure on this page comes from before it.

Cash runway does not apply, because Vertex generates operating cash; the runway guide covers the loss-making side. Value turns on how long the CF franchise lasts and what the pipeline adds. Of the six companies in the franchise concentration guide, only Moderna has a higher lead-product share (COVID vaccines, 93.1%); Gilead's HIV share is 70.5%.

How the Numbers Read

R&D was $3,910M in FY2025 (GAAP, excluding acquired in-process R&D), about a third of revenue. Cash from existing products pays for the next wave, the commercial-stage pattern set out in the Biotech Sector Primer.

The FY2025 results named two milestones. VX-828, a next-generation CF drug, was in a proof-of-concept study. Povetacicept, for the kidney disease IgA nephropathy, was being filed with the FDA in stages under the accelerated approval route. By the Q2 2026 results (August 2026), povetacicept was under review with a 30 November 2026 decision date, and VX-828 data were expected in the second half of 2026.

Their clinical risk belongs in a risk-adjusted NPV (rNPV), with the probability of success (PoS) in the cash flows. The industry benchmark, a BIO study of 2011-2020, gives 52.0% for Phase I→II and 7.9% from Phase I to approval.

Valuation Framework

Anchor the CF franchise on its filed FY2025 revenue of $11,151M; no one files a peak figure for a mature franchise. Add probability-weighted value for pipeline programmes (VX-828, povetacicept and others disclosed) at the model's default 10.0% nominal discount rate. Net cash comes from the balance sheet after the Crinetics deal, not the $12.3B at year-end 2025, and the acquired drugs need their own lines: PALSONIFY on its sales, atumelnant on rNPV.

If the CF line slows, group revenue slows almost one-for-one, because 92.9% of FY2025 revenue moves together.

What to Watch in the Financials

CF share (92.9%). TRIKAFTA/KAFTRIO was $10,313M and ALYFTREK $838M. A slowdown in the combined line moves the whole income statement. Once Crinetics is consolidated, PALSONIFY sales join the denominator, so the CF share will read lower even if CF itself does not change.

Pipeline milestones in 2026. The povetacicept decision (due 30 November 2026) and VX-828 proof-of-concept data are the nearest milestones outside CF. Model each with explicit phase probabilities, using disease-specific rates where they are sourced.

Key Risks

Single-franchise concentration. A competing CF regimen or pricing pressure would hit nearly all revenue at once, however much cash the franchise generates.

Clinical and regulatory risk. Povetacicept could be rejected or delayed at the FDA, and VX-828 could fail its proof-of-concept study.

Limited pipeline offset. Earlier-stage programmes add value only as they advance, so they cannot quickly replace lost CF revenue.